Eribulin: rediscovering tubulin as an anticancer target.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 19509144.
- Also identified by DOI 10.1158/1078-0432.CCR-09-1023.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Eribulin mesylate (E7389) is a synthetic analog of the marine macrolide halichondrin B, which acts as a novel microtubule modulator with a distinct mechanism of action. Two eribulin mesylate phase 1 studies exploring weekly and 3-weekly schedules are reported in this issue. These trials show linear pharmacokinetics, a toxicity profile consisting in neutropenia and fatigue, and early hints of antitumor activity. In this commentary we give a brief historical perspective of the halichondrins and put into context eribulin mesylate as a novel tubulin modulator.
Medical subject headings
- Antineoplastic Agents
- Furans
- Ketones
- Neoplasms
- Tubulin
- Tubulin Modulators